Andrew M. Waters

Goodwin Craig M, Waters Andrew M, Klomp Jennifer E, Javaid Sehrish, Bryant Kirsten L, Stalnecker Clint A, Drizyte-Miller Kristina, Papke Bjoern, Yang Runying, Amparo Amber M, Ozkan-Dagliyan Irem, Baldelli Elisa, Calvert Valerie, Pierobon Mariaelena, Sorrentino Jessica A, Beelen Andrew P, Bublitz Natalie, Luthen Maureen, Wood Kris C, Petricoin Emmanuel F, Sers Christine, McRee Autumn J, Cox Adrienne D, Der Channing J 2023. Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer Cancer Research, 83 1, 141-157

Cook, Danielle R; Kang, Melissa; Martin, Timothy D; Galanko, Joseph A; Loeza, Gabriela H; Trembath, Dimitri G; Justilien, Verline; Pickering, Karen A; Vincent, David F; Jarosch, Armin; Jurmeister, Philipp; Waters, Andrew M; Hibshman, Priya S; Campbell, Andrew D; Ford, Catriona A; Keku, Temitope O; Yeh, Jen Jen; Lee, Michael S; Cox, Adrienne D; Fields, Alan P; Sandler, Robert S; Sansom, Owen J; Sers, Christine; Schaefer, Antje; Der, Channing J 2022. Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. Cancer research, 82 1, 90-104

Huynh, Minh V; Hobbs, G Aaron; Schaefer, Antje; Pierobon, Mariaelena; Carey, Leiah M; Diehl, J Nathaniel; DeLiberty, Jonathan M; Thurman, Ryan D; Cooke, Adelaide R; Goodwin, Craig M; Cook, Joshua H; Lin, Lin; Waters, Andrew M; Rashid, Naim U; Petricoin, Emanuel F; Campbell, Sharon L; Haigis, Kevin M; Simeone, Diane M; Lyssiotis, Costas A; Cox, Adrienne D; Der, Channing J 2022. Functional and biological heterogeneity of KRASQ61 mutations. Science signaling, 15 746, eabn2694

Javaid, Sehrish; Schaefer, Antje; Goodwin, Craig M; Nguyen, Victoria V; Massey, Frances L; Pierobon, Mariaelena; Gambrell-Sanders, Da'Jhnae; Waters, Andrew M; Lambert, Kathryn N; Diehl, J Nathaniel; Hobbs, G Aaron; Wood, Kris C; Petricoin, Emanuel F; Der, Channing J; Cox, Adrienne D 2022. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular cancer therapeutics, 21 5, 762-774

Klomp, Jennifer E; Lee, Ye S; Goodwin, Craig M; Papke, Björn; Klomp, Jeff A; Waters, Andrew M; Stalnecker, Clint A; DeLiberty, Jonathan M; Drizyte-Miller, Kristina; Yang, Runying; Diehl, J Nathaniel; Yin, Hongwei H; Pierobon, Mariaelena; Baldelli, Elisa; Ryan, Meagan B; Li, Siqi; Peterson, Jackson; Smith, Amber R; Neal, James T; McCormick, Aaron K; Kuo, Calvin J; Counter, Christopher M; Petricoin, Emanuel F; Cox, Adrienne D; Bryant, Kirsten L; Der, Channing J 2021. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell reports, 37 9, 110060

Waters, Andrew M; Der, Channing J 2021. Validation of Isoform- and Mutation-Specific RAS Antibodies. Methods in molecular biology (Clifton, N.J.), 2262 , 91-103

Waters, Andrew M; Khatib, Tala O; Papke, Bjoern; Goodwin, Craig M; Hobbs, G Aaron; Diehl, J Nathaniel; Yang, Runying; Edwards, A Cole; Walsh, Katherine H; Sulahian, Rita; McFarland, James M; Kapner, Kevin S; Gilbert, Thomas S K; Stalnecker, Clint A; Javaid, Sehrish; Barkovskaya, Anna; Grover, Kajal R; Hibshman, Priya S; Blake, Devon R; Schaefer, Antje; Nowak, Katherine M; Klomp, Jennifer E; Hayes, Tikvah K; Kassner, Michelle; Tang, Nanyun; Tanaseichuk, Olga; Chen, Kaisheng; Zhou, Yingyao; Kalkat, Manpreet; Herring, Laura E; Graves, Lee M; Penn, Linda Z; Yin, Hongwei H; Aguirre, Andrew J; Hahn, William C; Cox, Adrienne D; Der, Channing J 2021. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell reports, 35 13, 109291

Hobbs, G Aaron; Baker, Nicole M; Miermont, Anne M; Thurman, Ryan D; Pierobon, Mariaelena; Tran, Timothy H; Anderson, Andrew O; Waters, Andrew M; Diehl, J Nathaniel; Papke, Bjoern; Hodge, Richard G; Klomp, Jennifer E; Goodwin, Craig M; DeLiberty, Jonathan M; Wang, Junning; Ng, Raymond W S; Gautam, Prson; Bryant, Kirsten L; Esposito, Dominic; Campbell, Sharon L; Petricoin, Emanuel F; Simanshu, Dhirendra K; Aguirre, Andrew J; Wolpin, Brian M; Wennerberg, Krister; Rudloff, Udo; Cox, Adrienne D; Der, Channing J 2020. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer discovery, 10 1, 104-123

Ozkan-Dagliyan, Irem; Diehl, J Nathaniel; George, Samuel D; Schaefer, Antje; Papke, Bjoern; Klotz-Noack, Kathleen; Waters, Andrew M; Goodwin, Craig M; Gautam, Prson; Pierobon, Mariaelena; Peng, Sen; Gilbert, Thomas S K; Lin, Kevin H; Dagliyan, Onur; Wennerberg, Krister; Petricoin, Emanuel F; Tran, Nhan L; Bhagwat, Shripad V; Tiu, Ramon V; Peng, Sheng-Bin; Herring, Laura E; Graves, Lee M; Sers, Christine; Wood, Kris C; Cox, Adrienne D; Der, Channing J 2020. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell reports, 31 11, 107764

Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2019. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 25 4, 628-640

Waters, Andrew M; Der, Channing J 2018. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor perspectives in medicine, 8 9,

Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel; Yi, Ming; Afghani, Shervin; Burgan, William; Fer, Nicole; Strathern, Leslie A; Powell, Katie; Smith, Brian; Waters, Andrew M; Drubin, David; Thomson, Ty; Liao, Rosy; Greninger, Patricia; Stein, Giovanna T; Murchie, Ellen; Cortez, Eliane; Egan, Regina K; Procter, Lauren; Bess, Matthew; Cheng, Kwong Tai; Lee, Chih-Shia; Lee, Liam Changwoo; Fellmann, Christof; Stephens, Robert; Luo, Ji; Lowe, Scott W; Benes, Cyril H; McCormick, Frank 2018. Differential Effector Engagement by Oncogenic KRAS. Cell reports, 22 7, 1889-1902

Waters, Andrew M; Ozkan-Dagliyan, Irem; Vaseva, Angelina V; Fer, Nicole; Strathern, Leslie A; Hobbs, G Aaron; Tessier-Cloutier, Basile; Gillette, William K; Bagni, Rachel; Whiteley, Gordon R; Hartley, James L; McCormick, Frank; Cox, Adrienne D; Houghton, Peter J; Huntsman, David G; Philips, Mark R; Der, Channing J 2017. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science signaling, 10 498,

Ye, Xiaoying; Chan, King C; Waters, Andrew M; Bess, Matthew; Harned, Adam; Wei, Bih-Rong; Loncarek, Jadranka; Luke, Brian T; Orsburn, Benjamin C; Hollinger, Bradley D; Stephens, Robert M; Bagni, Rachel; Martinko, Alex; Wells, James A; Nissley, Dwight V; McCormick, Frank; Whiteley, Gordon; Blonder, Josip 2016. Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget, 7 52, 86948-86971

Waters, Andrew M; Bagni, Rachel; Portugal, Franklin; Hartley, James L . Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. PloS one, 11 9, e0163272